Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer

Prostate cancer is the second leading cause of death from cancer among males in Western countries. It is also the most commonly diagnosed male cancer in Japan. The progression of prostate cancer is mainly influenced by androgens and the androgen receptor (AR). Androgen deprivation therapy is an established therapy for advanced prostate cancer; however, prostate cancers frequently develop resistance to low testosterone levels and progress to the fatal stage called castration-resistant prostate cancer (CRPC). Surprisingly, AR and the AR signaling pathway are still activated in most CRPC cases. To overcome this problem, abiraterone acetate and enzalutamide were introduced for the treatment of CRPC. Despite the impact of these drugs on prolonged survival, CRPC acquires further resistance to keep the AR pathway activated. Functional molecular studies have shown that some of the AR collaborative transcription factors (TFs), including octamer transcription factor (OCT1), GATA binding protein 2 (GATA2) and forkhead box A1 (FOXA1), still stimulate AR activity in the castration-resistant state. Therefore, elucidating the crosstalk between the AR and collaborative TFs on the AR pathway is critical for developing new strategies for the treatment of CRPC. Recently, many compounds targeting this pathway have been developed for treating CRPC. In this review, we summarize the AR signaling pathway in terms of AR collaborators and focus on pyrrole-imidazole (PI) polyamide as a candidate compound for the treatment of prostate cancer.

[1]  D. Tindall,et al.  Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. , 2008, Cancer research.

[2]  J. Hsieh,et al.  Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer* , 2005, Journal of Biological Chemistry.

[3]  J T Arnold,et al.  Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. , 2002, Endocrine-related cancer.

[4]  J. Kench,et al.  A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes , 2009, Oncogene.

[5]  H. Aburatani,et al.  Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth , 2016, Oncogene.

[6]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[7]  H. Aburatani,et al.  Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. , 2014, Molecular endocrinology.

[8]  K. Zaret,et al.  Specific interactions of the wing domains of FOXA1 transcription factor with DNA. , 2007, Journal of molecular biology.

[9]  Kosuke Saito,et al.  Preclinical Study of Novel Gene Silencer Pyrrole-Imidazole Polyamide Targeting Human TGF-β1 Promoter for Hypertrophic Scars in a Common Marmoset Primate Model , 2015, PloS one.

[10]  E. Antonarakis,et al.  Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born , 2012, Therapeutic advances in urology.

[11]  Jianfeng Xu,et al.  Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. , 2008, Neoplasia.

[12]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[13]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[14]  J. Grandis,et al.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[16]  H. Sugiyama,et al.  Pharmacokinetic modeling and prediction of plasma pyrrole-imidazole polyamide concentration in rats using simultaneous urinary and biliary excretion data. , 2009, Biological & pharmaceutical bulletin.

[17]  S. Balk,et al.  Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. , 2009, Cancer research.

[18]  G. Jenster,et al.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.

[19]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[20]  K. Pienta,et al.  Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide , 2015, PloS one.

[21]  Kai-Wen Huang,et al.  Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[23]  D. Aust,et al.  FISH Analysis of Gene Aberrations (MYC, CCND1, ERBB2, RB, and AR) in Advanced Prostatic Carcinomas Before and After Androgen Deprivation Therapy , 2000, Laboratory Investigation.

[24]  D C Rees,et al.  A structural basis for recognition of A.T and T.A base pairs in the minor groove of B-DNA. , 1998, Science.

[25]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[26]  Hiroshi Handa,et al.  A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress. , 2009, Genes & development.

[27]  M. Kimura,et al.  Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation , 2015, Cancer science.

[28]  Y. Hayashizaki,et al.  FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. , 2008, Biochemical and biophysical research communications.

[29]  M. Rubin,et al.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. , 2010, Neoplasia.

[30]  Qianben Wang,et al.  Phospho‐MED1‐enhanced UBE2C locus looping drives castration‐resistant prostate cancer growth , 2011, The EMBO journal.

[31]  L. Schwartz,et al.  Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. , 2009, European urology.

[32]  A. Chinnaiyan,et al.  Dual roles of PARP-1 promote cancer growth and progression. , 2012, Cancer discovery.

[33]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[34]  Gurmit Singh,et al.  Ets-1 Regulates Energy Metabolism in Cancer Cells , 2010, PloS one.

[35]  M. Ladomery,et al.  The oncogene ERG: a key factor in prostate cancer , 2016, Oncogene.

[36]  Peter B. Dervan,et al.  Recognition of the four Watson–Crick base pairs in the DNA minor groove by synthetic ligands , 1998, Nature.

[37]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[38]  N. Vogelzang,et al.  Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[39]  M. Gleave,et al.  Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer , 2014, Proceedings of the National Academy of Sciences.

[40]  Y. Furukawa,et al.  The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases* , 2013, The Journal of Biological Chemistry.

[41]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[42]  Jie Zhang,et al.  Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in Cancer , 2009, Cell.

[43]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[44]  P. Nelson,et al.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. , 2011, Cancer cell.

[45]  P. Sharp,et al.  The octamer binding transcription factor Oct-1 is a stress sensor. , 2005, Cancer research.

[46]  H. Aburatani,et al.  Androgen‐responsive long noncoding RNA CTBP1‐AS promotes prostate cancer , 2013, The EMBO journal.

[47]  K. H. Richter,et al.  The structure of chromatin. , 1971, Lancet.

[48]  Carla Grandori,et al.  c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I , 2005, Nature Cell Biology.

[49]  Takahito Hara,et al.  Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.

[50]  H. Klocker,et al.  Androgen receptor status of lymph node metastases from prostate cancer , 1996, The Prostate.

[51]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[52]  Jindan Yu,et al.  Cooperativity and Equilibrium with FOXA1 Define the Androgen Receptor Transcriptional Program , 2014, Nature Communications.

[53]  P. Santisteban,et al.  The Forkhead Factor FoxE1 Binds to the Thyroperoxidase Promoter during Thyroid Cell Differentiation and Modifies Compacted Chromatin Structure , 2007, Molecular and Cellular Biology.

[54]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[55]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.

[56]  R. Dulbecco.  Genes in cancer. , 1983, Folia biologica.

[57]  D. Tindall,et al.  Androgen modulation of coregulator expression in prostate cancer cells. , 2009, Molecular endocrinology.

[58]  H. Sugiyama,et al.  Discrimination of Hairpin Polyamides with an α-Substituted-γ-aminobutyric Acid as a 5‘-TG-3‘ Reader in DNA Minor Groove , 2006 .

[59]  K. Nephew,et al.  Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer , 2014, Nucleic acids research.

[60]  N. Mitsiades,et al.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer , 2016, Hormones and Cancer.

[61]  I. Mills,et al.  New androgen receptor genomic targets show an interaction with the ETS1 transcription factor , 2007, EMBO reports.

[62]  R. Matusik,et al.  NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. , 2014, Molecular endocrinology.

[63]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[64]  Myles A Brown,et al.  Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. , 2005, Molecular cell.

[65]  R. Vessella,et al.  Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.

[66]  S. Dhanasekaran,et al.  Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. , 2009, Cancer research.

[67]  R. Place,et al.  Targeted induction of endogenous NKX3‐1 by small activating RNA inhibits prostate tumor growth , 2013, The Prostate.

[68]  D. Horsfall,et al.  Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. , 1994, Cancer research.

[69]  T. Kodama,et al.  A GATA‐specific inhibitor (K‐7174) rescues anemia induced by IL‐1β, TNF‐α, or l‐NMMA , 2003 .

[70]  G. Coetzee,et al.  Genomic Androgen Receptor-Occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional Capacity , 2008, PloS one.

[71]  P. Dervan,et al.  Recognition of the DNA minor groove by pyrrole-imidazole polyamides. , 2003, Current opinion in structural biology.

[72]  H. Scher,et al.  Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors , 2012, Clinical Cancer Research.

[73]  Arthur R. Brothman,et al.  Mutation of the MXI1 gene in prostate cancer , 1995, Nature Genetics.

[74]  M T D Cronin,et al.  A review of the electrophilic reaction chemistry involved in covalent DNA binding , 2010, Critical reviews in toxicology.

[75]  Frank R. Lin,et al.  Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. , 2002, Molecular cell.

[76]  K. Knudsen,et al.  Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer , 2010, Trends in Endocrinology & Metabolism.

[77]  D. Tindall,et al.  Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.

[78]  R. T. Curtis,et al.  A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. , 1997, Genomics.

[79]  G. Prendergast,et al.  Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma , 2000, International journal of cancer.

[80]  Peter B. Dervan,et al.  Allosteric modulation of DNA by small molecules , 2009, Proceedings of the National Academy of Sciences.

[81]  Karl R. Wotton,et al.  Conservation of gene linkage in dispersed vertebrate NK homeobox clusters , 2009, Development Genes and Evolution.

[82]  R. Trumbly,et al.  C/EBPα redirects androgen receptor signaling through a unique bimodal interaction , 2010, Oncogene.

[83]  T. Visakorpi,et al.  Genetic alterations in hormone-refractory recurrent prostate carcinomas. , 1998, The American journal of pathology.

[84]  Zhaohui S. Qin,et al.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.

[85]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[86]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.

[87]  I. Mills,et al.  The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. , 2013, Cancer cell.

[88]  J. Darnell,et al.  Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. , 1995, Annual review of biochemistry.

[89]  Wei Yan,et al.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.

[90]  S. Hilsenbeck,et al.  GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex , 2014, Proceedings of the National Academy of Sciences.

[91]  M. Mann.  Transcription Factor Decoys: A New Model for Disease Intervention , 2005, Annals of the New York Academy of Sciences.

[92]  M. Frydenberg,et al.  A preclinical xenograft model of prostate cancer using human tumors , 2013, Nature Protocols.

[93]  Renjie Jin,et al.  The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. , 2003, Molecular endocrinology.

[94]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[95]  C. Leonetti,et al.  Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice. , 1996, Journal of the National Cancer Institute.

[96]  R. Place,et al.  Small dsRNAs induce transcriptional activation in human cells , 2006, Proceedings of the National Academy of Sciences.

[97]  Tanya K. Day,et al.  Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. , 2016, Endocrine-related cancer.

[98]  Kosuke Saito,et al.  Transcriptional inhibition of progressive renal disease by gene silencing pyrrole-imidazole polyamide targeting of the transforming growth factor-β1 promoter. , 2011, Kidney international.

[99]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[100]  J. Nevins,et al.  Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes , 1995, Molecular and cellular biology.

[101]  J. Eeckhoute,et al.  Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. , 2007, Cancer research.

[102]  Tsung-Cheng Chang,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.

[103]  Wing-Kin Sung,et al.  Integration of Regulatory Networks by NKX3-1 Promotes Androgen-Dependent Prostate Cancer Survival , 2012, Molecular and Cellular Biology.

[104]  P. Walsh,et al.  Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy , 1991, Cancer.

[105]  Marc A. Thomas,et al.  ETS1 regulates NKX3.1 5′ promoter activity and expression in prostate cancer cells , 2011, The Prostate.

[106]  D C Rees,et al.  Structural effects of DNA sequence on T.A recognition by hydroxypyrrole/pyrrole pairs in the minor groove. , 2000, Journal of molecular biology.

[107]  C. Huggins.  EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE. , 1942, Annals of surgery.

[108]  W. Figg,et al.  The Mutated Androgen Receptor and Its Implications for the Treatment of Metastatic Carcinoma of the Prostate , 1996, Pharmacotherapy.

[109]  Juli D. Klemm,et al.  Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules , 1994, Cell.

[110]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[111]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[112]  Jérôme Eeckhoute,et al.  Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer , 2007 .

[113]  P. Dervan,et al.  Enhancing the cellular uptake of Py–Im polyamides through next-generation aryl turns , 2012, Nucleic acids research.

[114]  T. H. van der Kwast,et al.  Androgen receptors in untreated and treated prostatic intraepithelial neoplasia. , 1996, European urology.

[115]  O. Sartor,et al.  Castration-resistant prostate cancer: adaptive responses in the androgen axis. , 2014, Cancer treatment reviews.

[116]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[117]  E. Gelmann,et al.  NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage. , 2015, Cancer research.

[118]  J. Trauger,et al.  Recognition of DNA by designed ligands at subnanomolar concentrations , 1996, Nature.

[119]  Glen Kristiansen,et al.  Tumorigenesis and Neoplastic Progression FOXA 1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castration-Resistant Prostate Cancer , 2012 .

[120]  P. Dervan,et al.  Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide , 2007, Proceedings of the National Academy of Sciences.

[121]  D. Rees,et al.  Structural basis for G•C recognition in the DNA minor groove , 1998, Nature Structural Biology.

[122]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[123]  J. Isaacs,et al.  A history of prostate cancer treatment , 2002, Nature Reviews Cancer.

[124]  G. Coetzee,et al.  Inhibition of AR‐mediated transcription by binding of Oct1 to a motif enriched in AR‐occupied regions , 2009, The Prostate.

[125]  Yukio Homma,et al.  RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer , 2014, Oncotarget.

[126]  Q. Hu,et al.  NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis , 2016, Cell Discovery.

[127]  Heikki Lehväslaiho,et al.  The Androgen Receptor Gene Mutations Database , 1998, Nucleic Acids Res..

[128]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[129]  D. Banerjee,et al.  Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer , 2013, Cancer biology & therapy.

[130]  D. Banerjee,et al.  A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts , 2014, Oncotarget.

[131]  K. Pienta,et al.  A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.

[132]  H. Klocker,et al.  Distant metastases from prostatic carcinoma express androgen receptor protein. , 1995, Cancer research.

[133]  M. Menon,et al.  Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. , 2007, Cancer research.

[134]  Jindan Yu,et al.  FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression , 2016, Oncogene.

[135]  K. Zaret,et al.  GATA transcription factors as potentiators of gut endoderm differentiation. , 1998, Development.

[136]  T. Fujino,et al.  Genomic organization and transcription units of the human acyl-CoA synthetase 3 gene. , 2001, Gene.

[137]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[138]  A. Üren,et al.  YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell Invasion , 2011, PloS one.

[139]  D. Tindall,et al.  Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. , 2007, Endocrine reviews.

[140]  D. Beach,et al.  Myc confers androgen-independent prostate cancer cell growth. , 2003, The Journal of clinical investigation.

[141]  Desok Kim,et al.  Androgen receptor gene amplification and protein expression in recurrent prostate cancer. , 2003, The Journal of urology.

[142]  H. He,et al.  SOX9 drives WNT pathway activation in prostate cancer. , 2016, The Journal of clinical investigation.

[143]  D. Turner,et al.  ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer , 2008, Expert review of anticancer therapy.

[144]  Charles M Perou,et al.  FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival , 2007, Clinical Cancer Research.

[145]  A. Chinnaiyan,et al.  BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer , 2016, Molecular Cancer Research.

[146]  S. Balk,et al.  Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence , 2004, Journal of cellular biochemistry.

[147]  Y. Homma,et al.  CtBP2 modulates the androgen receptor to promote prostate cancer progression. , 2014, Cancer research.

[148]  J. Carroll,et al.  Pioneer transcription factors: establishing competence for gene expression. , 2011, Genes & development.

[149]  S. Sakamoto,et al.  Interaction of Oct‐1 and automodification domain of poly(ADP‐ribose) synthetase , 1998, FEBS letters.

[150]  R. Morishita,et al.  Gene therapy using ets‐1 transcription factor decoy for peritoneal dissemination of gastric cancer , 2007, International journal of cancer.

[151]  Jian Hui Wu,et al.  The androgen receptor gene mutations database (ARDB): 2004 update , 2004, Human mutation.

[152]  C. Catapano,et al.  Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene. , 2002, Nucleic acids research.

[153]  Randy S. Schrecengost,et al.  Molecular pathogenesis and progression of prostate cancer. , 2013, Seminars in oncology.

[154]  G. Shulman,et al.  Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.

[155]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[156]  V. Findlay,et al.  ETS1 transcriptional activity is increased in advanced prostate cancer and promotes the castrate-resistant phenotype. , 2012, Carcinogenesis.

[157]  Y. Homma,et al.  Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer , 2012, International journal of cancer.

[158]  N. Hay,et al.  Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. , 1998, Molecular endocrinology.

[159]  M. Rubin,et al.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.

[160]  D. Levy,et al.  STAT3 regulated ARF expression suppresses prostate cancer metastasis , 2015, Nature Communications.

[161]  P. Peixoto,et al.  Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines , 2012, Nucleic acids research.

[162]  K. Takayama,et al.  Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth , 2014, Cancer science.

[163]  M. Kitamura,et al.  Suppression of cytokine response by GATA inhibitor K-7174 via unfolded protein response. , 2007, Biochemical and biophysical research communications.

[164]  松田 裕之.  Development of gene silencing pyrrole-imidazole polyamide targeting the TGF-β1 promoter for treatment of progressive renal diseases , 2006 .

[165]  J. Bono,et al.  Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. , 2012, European journal of cancer.

[166]  S. Srivastava,et al.  TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation , 2008, Oncogene.

[167]  T. Kodama,et al.  A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA. , 2000, Biochemical and biophysical research communications.

[168]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[169]  G. Jenster,et al.  Identification of Two Transcription Activation Units in the N-terminal Domain of the Human Androgen Receptor (*) , 1995, The Journal of Biological Chemistry.

[170]  A. Giordano,et al.  RB and cell cycle progression , 2006, Oncogene.

[171]  C. Bieberich,et al.  MYC and Prostate Cancer. , 2010, Genes & cancer.

[172]  John S Lazo,et al.  Improved low molecular weight Myc-Max inhibitors , 2007, Molecular Cancer Therapeutics.

[173]  P. Nelson,et al.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. , 2010, The Journal of clinical investigation.

[174]  Lara J. Monteiro,et al.  FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer , 2014, Oncogene.

[175]  J. Pow-Sang,et al.  Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.

[176]  H. Sugiyama,et al.  Pharmacokinetics of pyrrole‐imidazole polyamides after intravenous administration in rat , 2009, Biopharmaceutics & drug disposition.

[177]  Wouter de Laat,et al.  Quantitative analysis of chromosome conformation capture assays (3C-qPCR) , 2007, Nature Protocols.